As shown in Table 3 the occurrence of endocrinopathy revealed a significant impact of first-line therapy (p = 0.013) and the combination of PD-1 with CTLA-4 therapy vs. monotherapy (p = 0.007). This evidence concerns the gene PDCD1 and endocrine system disorder.